Glintborg B, et al. – The physicians reviewed the clinical outcomes of a nationwide non–medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT–P13) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). They found no negative impact of a non–medical switch to CT–P13 on disease activity, in arthritis patients treated with INX for median >6 years. However, adjusted 1–year CT–P13 retention rate was slightly lower than for INX.